Business Wire

AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial

Jaa

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served as the basis for the recent US Food and Drug Administration (FDA) accelerated approval of Calquence (acalabrutinib). The findings were presented for the first time during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA and demonstrate the safety profile and efficacy of acalabrutinib in the management of previously-treated mantle cell lymphoma (MCL).

Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The results presented for the first time to the medical community highlight the potential of Calquence as a treatment for people with relapsed or refractory mantle cell lymphoma, a life-threatening form of blood cancer. These data reinforce the important progress of our clinical development programme as well as our commitment to advancing the treatment of patients with blood cancers.”

Michael L. Wang, MD, Professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, and Principal Investigator of the ACE-LY-004 MCL clinical trial, said: “Most people living with mantle cell lymphoma will unfortunately relapse, and new treatment options are greatly needed. As shown by the consistent overall response rates observed in this trial across several pre-specified subgroups, acalabrutinib is a welcome new treatment option for certain patients with this aggressive blood cancer.”

Summary of key investigator-assessed efficacy results from ACE-LY-004 (15.2 months median follow-up):

Efficacy measure       Patients (percent response)

Overall response rate
(Complete response + partial response)
     Complete response
     Partial response

      81% (95% CI: 73,87)

 

40% (95% CI: 31,49)

41% (95% CI: 32,50)

Stable disease       9% (95% CI: 5,15)
Progressive disease       8% (95% CI: 4,14)
Not evaluable       2% (95% CI: 1,7)

Per the 2014 Lugano classification response criteria for non-Hodgkin lymphoma; high concordance was observed between investigator-assessed and independent review committee-assessed overall response and complete response rates, respectively.

The overall response rate was consistent across multiple subgroups including age, tumour burden and number or type of prior treatments. The secondary endpoint of median duration of response had not yet been reached at 15.2 months median follow-up. The median time-to-response, an exploratory endpoint, was 1.9 months. After 12 months of treatment, 72% (95% CI: 62,80) of patients were still responding to acalabrutinib treatment. The secondary endpoints of progression-free survival and overall survival had not yet been reached; at 12 months, the progression-free survival and overall survival rates were 67% (95% CI: 58,75) and 87% (95% CI: 79,92), respectively.

In this trial, the most common non-haematological adverse reactions (reported in ≥20% of patients at a median follow-up time of 15.2 months) were headache (38%), diarrhoea (30%), fatigue (26%) and myalgia (21%), per investigator assessment. Grade 3 or 4 adverse reactions (≥5%) included anaemia (12%), neutropenia (11%), and pneumonia (6%).

Calquence was granted accelerated approval by the US FDA in October 2017 for the treatment of adult patients with MCL who have received at least one prior therapy. This indication is approved based on overall response rate, and continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

– ENDS –

NOTES TO EDITORS

About Calquence (acalabrutinib)
Acalabrutinib (previously known as ACP-196) is a selective inhibitor of BTK. Acalabrutinib binds covalently to BTK, thereby inhibiting its activity, and has demonstrated this with minimal interactions with other immune cells in pre-clinical studies.2,3,4 In B cells, BTK signalling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis and adhesion.2

Calquence was granted accelerated approval by the US Food and Drug Administration (FDA) in October 2017 for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Acalabrutinib is not approved for use outside of its labelled indication in the US and is not approved in any other country at this time.

Acalabrutinib is also in development for the treatment of multiple B-cell malignancies and other blood cancers including 1st-line MCL, chronic lymphocytic leukaemia (CLL), Waldenström macroglobulinaemia (WM), follicular lymphoma, diffuse large B-cell lymphoma, and multiple myeloma. It is also being developed as a monotherapy and in combination trials for solid tumours. More than 35 clinical trials across 40 countries with more than 2,500 patients are underway or have been completed.5

Acalabrutinib was granted Orphan Drug Designation by the European Commission in March 2016 and the US FDA in 2015 for the treatment of patients with CLL, MCL and WM, and Breakthrough Therapy Designation in August 2017 by the US FDA for the treatment of patients with MCL who have received at least one prior therapy.

About Mantle Cell Lymphoma (MCL)
MCL is an aggressive B-cell non-Hodgkin lymphoma (NHL) with poor prognosis.6,7,8,9 MCL accounts for approximately 3% to 6% of new NHL cases in Western countries each year; in the US, approximately 3,300 new cases of MCL are diagnosed each year.6,10 The median age at diagnosis is 68 years, with a 3:1 male predominance.7 While MCL patients initially respond to treatment, there is a high relapse rate.6

About the ACE-LY-004 Trial
ACE-LY-004 is a Phase II open-label, single-arm clinical trial in 124 adult patients with relapsed or refractory MCL. The trial showed that 81% (95% CI: 73,87) of patients treated with acalabrutinib achieved an overall response; 40% (95% CI: 31,49) achieved a complete response and 41% (95% CI: 32,50) achieved a partial response, per 2014 Lugano classification as assessed by investigator.1

About AstraZeneca in Oncology
AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly-growing portfolio of new medicines that have the potential to transform patients’ lives and the Company’s future. With at least six new medicines aimed to be launched between 2014 and 2020 and a broad pipeline of small molecules and biologics in development, we are committed to advance New Oncology as one of AstraZeneca’s five Growth Platforms focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities, we actively pursue innovative partnerships and investments that accelerate the delivery of our strategy as illustrated by our investment in Acerta Pharma in haematology.

By harnessing the power of four scientific platforms – Immuno-Oncology, Tumour Drivers and Resistance, DNA Damage Response and Antibody Drug Conjugates – and by championing the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death.

About Acerta Pharma
Acerta Pharma, a member of the AstraZeneca Group, is creating novel therapies intended for the treatment of cancer and autoimmune diseases. AstraZeneca acquired a majority stake interest in Acerta Pharma, which serves as AstraZeneca’s haematology research and development centre of excellence. For more information, please visit www.acerta-pharma.com.

About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Intended audiences
This press release is issued from AstraZeneca Corporate Headquarters in Cambridge, UK and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where AstraZeneca conducts business.

___________________________

1 Data on File. REF-23706. AstraZeneca Pharmaceuticals LP, Wilmington, DE.
2 Calquence (acalabrutinib) Prescribing Information. AstraZeneca Pharmaceuticals LP, Wilmington, DE
3 Covey T, Barf T, Gulrajani M, Krantz F, van Lith B, Bibikova E, et al. Abstract 2596: ACP-196: a novel covalent Bruton’s tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients. Cancer Res. 2015;75(15 Supplement):2596.
4 Harrington BK, Gulrajani M, Covey T, Kaptein A, Van Lith B, Izumi R, et al. ACP-196 is a second generation inhibitor of Bruton tyrosine kinase (BTK) with enhanced target specificity. Blood. 2015;126(23):2908.
5 Data on File. REF US-15441. AstraZeneca Pharmaceuticals LP, Wilmington, DE.
6 Leukemia & Lymphoma Society. Mantle Cell Lymphoma Facts. https://www.lls.org/sites/default/files/file_assets/mantlecelllymphoma.pdf. Accessed June 2017
7 Cheah CY, Seymour JF, Wang M. Mantle Cell Lymphoma. Journal of Clinical Oncology 34, no. 11 (April 2016) 1256-1269.
8 Hoster E, Klapper W et al. Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network. Journal of Clinical Oncology 2014;32:1338-1346.
9 Dreyling M, Ferrero S. The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive? Haematologica 2016 Volume 101(2):104-114
10 Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66:443-459.

Contact information

AstraZeneca
Karen Birmingham: +44 781 852 4012
Mike Hayes: +1 301-398-0221
Hugues Joublin: +1 301-398-3041

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

AECOM defines infrastructure’s next chapter with launch of its inaugural global report: The Future of Infrastructure23.1.2018 08:00Tiedote

AECOM (NYSE:ACM), a premier, fully integrated global infrastructure firm, released its inaugural global research report today, The Future of Infrastructure, which harnesses survey data and opinions from more than 500 industry decision-makers working in major organizations across the North America, Europe and the Asia-Pacific regions. With eight in 10 respondents agreeing this is a pivotal time for the industry, the report examines the problems, priorities and potential in delivering major infrastructure projects around the world. The Future of Infrastructure report can be accessed at: infrastructure.aecom.com . “Infrastructure networks and systems around the globe are under considerable strain. Amid urbanization, climate change and the dizzying pace of technological advances, just narrowing the gap that exists is no longer a sufficient goal. What’s needed is a giant leap forward,” said Michael S. Burke, AECOM’s chairman and chief executive officer. “Our report makes clear that by focus

Neil Diamond Announces Retirement from Concert Touring; Australian and New Zealand Tour Dates Cancelled23.1.2018 06:18Tiedote

Legendary singer, songwriter and performer Neil Diamond today announced his retirement from touring due to his recent diagnosis of Parkinson’s disease. The onset of the disease has made it difficult to travel and perform on a large scale basis but will allow Mr. Diamond to continue his writing, recording and development of new projects. Based on his doctors’ advice, the third leg of Diamond’s 50th Anniversary tour, set to land in Australia and New Zealand this March, has been cancelled. “It is with great reluctance and disappointment that I announce my retirement from concert touring. I have been so honored to bring my shows to the public for the past 50 years,” said Neil Diamond. “My sincerest apologies to everyone who purchased tickets and were planning to come to the upcoming shows. I plan to remain active in writing, recording and other projects for a long time to come. My thanks go out to my loyal and devoted audiences around the world. You will always have my appreciation for you

Logitech Delivers Record Sales, Up 22%23.1.2018 05:00Tiedote

Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the third quarter of Fiscal Year 2018. Q3 sales were an all-time record $812 million, up 22 percent in US dollars and 18 percent in constant currency, compared to Q3 of the prior year. Q3 GAAP operating income amounted to $100 million, compared to $96 million in the same quarter a year ago. Q3 GAAP earnings per share (EPS) amounted to $0.48, compared to $0.59 in the same quarter a year ago. GAAP profitability was impacted by a one-time $16 million net tax expense following the reduction in the U.S. federal income tax rate and other reforms. Q3 non-GAAP operating income grew 18 percent to $117 million, compared to $99 million in the same quarter a year ago. Q3 non-GAAP EPS grew 16 percent to $0.65, compared to $0.56 in the same quarter a year ago. Cash flow from operations grew 27 percent to $189 million, the highest quarterly level ever. “This holiday quarter, we’ve delivered our highest quarterly s

bitFlyer Launches in Europe and Becomes the World’s First Bitcoin Exchange to Be Regulated in Japan, the US and Europe23.1.2018 03:01Tiedote

bitFlyer, the Tokyo-based operator of the world’s largest1 Bitcoin exchange, today announced its launch into Europe. Having been granted a Payment Institution (PI) license to operate in the European Union it has become the first Bitcoin exchange to be regulated in Japan, the US and Europe, making it the most compliant virtual currency exchange in the world. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180122006686/en/ bitFlyer CEO, Yuzo Kano, with Luxembourg Minister of Finance, Pierre Gramegna. (Photo: Business Wire) bitFlyer’s launch into Europe comes hot on the heels of explosive growth in Japan and launch in the US in 2017. With 25 percent2 of worldwide bitcoin exchange volumes being facilitated by bitFlyer and over $250bn in virtual currency traded on its platform in 2017, bitFlyer is the world’s largest Bitcoin exchange and the only one licensed in Europe that will allow users to trade with Japan, the world’s largest

Corsearch Names Diane Plaut as Global General Counsel and Head of HR23.1.2018 00:00Tiedote

Corsearch, a trademark and domain solutions leader, is pleased to announce that Diane Plaut has joined the company as Global General Counsel and Head of HR, reporting to President and CEO Tobias Hartmann. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180122006527/en/ Diane Plaut, Global General Counsel and Head of HR, Corsearch (Photo: Business Wire) A long-time Corsearch Advisory Board member, client, and collaborator, Ms. Plaut brings to Corsearch over 25 years of experience in global intellectual property law, IP portfolio management, brand protection and enforcement, corporate law, privacy, and compliance. Ms. Plaut’s arrival comes as Corsearch begins a new chapter as an independent company, following its acquisition by Audax Private Equity earlier this month. “Diane is a born leader who is deeply knowledgeable about Corsearch products and services and the industry we serve,” said Mr. Hartmann. “Her passion for our compa

Bacardi to Acquire Patrón Tequila22.1.2018 23:28Tiedote

Family-owned Bacardi Limited, the largest privately held spirits company in the world, announced today that it is expanding its portfolio of premium spirits with a definitive agreement to acquire 100% ownership of Patrón Spirits International AG and its PATRÓN® brand, the world’s top-selling ultra-premium tequila. The transaction, which is subject to customary closing conditions, follows the successful relationship the companies have had for nearly a decade since Bacardi’s initial acquisition of a significant minority stake in Patrón in 2008. The transaction reflects an enterprise value for Patrón of US$5.1 billion and is expected to close in the first half of 2018. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180122006459/en/ Bacardi agrees to acquire 100% ownership of Patrón Spirits International and its PATRÓN® brand, the world’s top-selling ultra-premium tequila. (Photo: Business Wire) According to the most recent IWSR

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme